Compare the effectiveness of this GLP-1 agonist with other similar treatments for type 2 diabetes

If you have been living with type 2 diabetes and feel overwhelmed by the sheer number of treatment options available, you are certainly not alone. From older oral medications like metformin to the newer injectable GLP-1 receptor agonists, the landscape of diabetes management has changed dramatically over the past decade, and knowing which treatment is right for you can feel like an impossible task. Whether you are newly diagnosed, struggling to hit your HbA1c targets, or simply wondering whether switching medications might serve you better, this guide is here to cut through the confusion and give you clear, evidence-based information.

Quick Summary

GLP-1 receptor agonists have transformed type 2 diabetes care by offering meaningful HbA1c reductions alongside additional benefits such as weight loss and cardiovascular protection. Understanding how different agents in this class compare can help you and your prescriber make a more informed treatment decision.

• GLP-1 agonists work by mimicking the natural incretin hormone to stimulate insulin release and suppress glucagon
• Tirzepatide (Mounjaro) is a dual GIP/GLP-1 agonist and currently demonstrates the greatest HbA1c and weight reductions in clinical trials
• Semaglutide (Ozempic/Wegovy) is one of the most widely prescribed and well-studied GLP-1 agonists in the UK
• Older agents like exenatide and liraglutide remain effective but generally produce more modest results compared to newer options
• Choice of treatment depends on individual factors including HbA1c level, weight, cardiovascular risk, and tolerability

Table of Contents

1. What Are GLP-1 Agonists and How Do They Work?
2. Tirzepatide vs Semaglutide: The Head-to-Head Evidence
3. How Older GLP-1 Agents Like Exenatide and Liraglutide Compare
4. GLP-1 Agonists vs Other Type 2 Diabetes Medications
5. Cardiovascular and Renal Benefits: Which GLP-1 Has the Strongest Evidence?
6. Side Effects and Tolerability Across GLP-1 Treatments
7. GLP-1 Treatment Comparison Table
8. Key Takeaways
9. When to Seek Professional Advice
10. Scientific References
11. FAQs

What Are GLP-1 Agonists and How Do They Work?

GLP-1, or glucagon-like peptide-1, is a hormone that your gut naturally releases after eating. It plays a central role in regulating blood glucose by stimulating the pancreas to produce insulin in a glucose-dependent manner, suppressing glucagon secretion, slowing gastric emptying, and reducing appetite. In people with type 2 diabetes, this natural response is often blunted, which is where GLP-1 receptor agonists come in — they mimic and amplify these effects artificially.

Medications in this class include semaglutide (sold as Ozempic for diabetes and Wegovy for weight management), tirzepatide (Mounjaro), dulaglutide (Trulicity), liraglutide (Victoza/Saxenda), and exenatide (Byetta/Bydureon). Each of these works on the same basic principle but differs in molecular structure, receptor binding affinity, dosing frequency, and clinical outcomes. When you want to compare the effectiveness of this GLP-1 agonist with other similar treatments for type 2 diabetes, it is important to look beyond simple blood sugar numbers and consider cardiovascular protection, weight outcomes, tolerability, and long-term adherence.

Understanding how these medications work at a mechanistic level also helps explain why they differ in potency. Some agents, like tirzepatide, act on two incretin receptors simultaneously — the GIP (glucose-dependent insulinotropic polypeptide) receptor as well as the GLP-1 receptor — giving it a dual mechanism that amplifies its effects considerably. This is why clinical trial data for tirzepatide is often more impressive than that for single-receptor GLP-1 agonists.

• GLP-1 agonists stimulate insulin only when blood glucose is elevated, reducing hypoglycaemia risk
• They slow gastric emptying, which helps reduce post-meal glucose spikes
• Appetite suppression contributes to weight loss in many patients
• Some agents in this class have proven cardiovascular and renal protective effects

Tirzepatide vs Semaglutide: The Head-to-Head Evidence

The SURPASS-2 trial published in the New England Journal of Medicine was one of the first major head-to-head comparisons between tirzepatide and semaglutide 1mg. The results were striking. At the highest tirzepatide dose of 15mg, participants achieved an average HbA1c reduction of around 2.46% compared to 1.86% with semaglutide 1mg. Weight loss was also substantially greater with tirzepatide, with some participants losing an average of 13.1kg compared to 6.7kg on semaglutide 1mg. These are clinically significant differences that have influenced prescribing guidelines globally.

Semaglutide itself is no slouch. The SUSTAIN trial programme demonstrated consistent HbA1c reductions of between 1.2% and 1.8% across various doses, and the PIONEER series of trials showed that oral semaglutide could achieve comparable reductions to the injectable form. Semaglutide also has robust cardiovascular outcome data from the SUSTAIN-6 trial, showing significant reductions in major adverse cardiovascular events (MACE). If you are interested in how long it takes for GLP-1 treatments to take effect, the article on how long does it take for GLP-1 to kick in provides useful context.

For people living with type 2 diabetes who also struggle with excess weight, tirzepatide presents a particularly compelling option. The combination of superior HbA1c lowering and greater weight reduction can address two major risk factors simultaneously. However, semaglutide remains an excellent and well-tolerated choice for many patients, particularly those with established cardiovascular disease where its outcomes evidence is most robust.

• Tirzepatide reduces HbA1c more than semaglutide 1mg in direct comparison trials
• Tirzepatide produces approximately double the weight loss of semaglutide 1mg
• Semaglutide has stronger published cardiovascular outcomes evidence at present
• Both medications are administered once weekly by subcutaneous injection
• Semaglutide is available in an oral formulation; tirzepatide is injection only

How Older GLP-1 Agents Like Exenatide and Liraglutide Compare

Before semaglutide and tirzepatide dominated the landscape, liraglutide and exenatide were the mainstays of GLP-1 therapy. Liraglutide (Victoza) was the first once-daily GLP-1 agonist to gain widespread use and was a genuine landmark medication when it launched. The LEADER cardiovascular outcomes trial showed liraglutide significantly reduced the risk of major cardiovascular events in high-risk patients with type 2 diabetes, making it one of the first diabetes drugs to demonstrate meaningful cardiovascular benefit.

However, liraglutide typically produces HbA1c reductions of around 1.0% to 1.5% and weight loss of approximately 2 to 4kg, which is considerably less impressive than the newer agents. Exenatide, available in a twice-daily formulation (Byetta) and a once-weekly extended-release version (Bydureon), produces similar or slightly lower HbA1c reductions and modest weight loss. One advantage of exenatide is its longer track record and, in some cases, a lower cost, which can be a relevant factor for patients funding treatment privately.

Dulaglutide (Trulicity) sits somewhere in the middle of the GLP-1 spectrum. Once-weekly dosing makes it more convenient than twice-daily exenatide, and the REWIND trial showed cardiovascular benefits even in patients with lower baseline cardiovascular risk — a finding that distinguished it somewhat from liraglutide. HbA1c reductions with dulaglutide are generally in the range of 1.0% to 1.6%, and weight loss is modest at around 1 to 3kg.

• Liraglutide and exenatide are older agents with established safety records but modest outcomes
• Liraglutide has proven cardiovascular benefit from the LEADER trial
• Dulaglutide offers convenient once-weekly dosing and REWIND cardiovascular data
• None of the older agents match tirzepatide or higher-dose semaglutide for HbA1c or weight reduction

GLP-1 Agonists vs Other Type 2 Diabetes Medications

To put GLP-1 agonists in proper context, it is helpful to compare them against the other major drug classes used in type 2 diabetes management. Metformin remains the first-line agent recommended by NICE and most international guidelines. It is cheap, well tolerated, and reduces HbA1c by approximately 1.0% to 1.5%, but it produces little to no weight loss and has no meaningful cardiovascular outcome data of its own.

SGLT-2 inhibitors such as empagliflozin (Jardiance) and dapagliflozin (Forxiga) are another important class. They work by preventing glucose reabsorption in the kidneys and produce HbA1c reductions of 0.5% to 1.0%, along with modest weight loss of 2 to 4kg and meaningful reductions in heart failure hospitalisations and kidney disease progression. They are often used in combination with GLP-1 agonists rather than as an either-or choice. For patients interested in understanding more about monitoring tools used alongside these treatments, GLP-1 monitoring tools for home use is worth reading.

DPP-4 inhibitors like sitagliptin (Januvia) also work through the incretin pathway but are far less potent than GLP-1 agonists. They produce HbA1c reductions of around 0.5% to 0.8% and are weight neutral. Sulphonylureas such as gliclazide are effective at lowering blood sugar but carry a significant risk of hypoglycaemia and can promote weight gain — a disadvantage when most people with type 2 diabetes are already managing excess weight. GLP-1 agonists avoid both of these drawbacks, which is a key reason they have become preferred agents in modern guidelines.

• Metformin remains first-line but has limited glucose-lowering potency compared to newer agents
• SGLT-2 inhibitors complement GLP-1 agonists well and have strong kidney and heart failure data
• DPP-4 inhibitors are weaker and weight neutral compared to GLP-1 agonists
• Sulphonylureas carry hypoglycaemia risk and are associated with weight gain
• GLP-1 agonists offer a unique combination of HbA1c lowering, weight loss, and cardiovascular protection

Cardiovascular and Renal Benefits: Which GLP-1 Has the Strongest Evidence?

Cardiovascular disease is the leading cause of death in people with type 2 diabetes, so the cardiovascular profile of any treatment is arguably as important as its glucose-lowering ability. All major GLP-1 agonists have been studied in large cardiovascular outcomes trials as required by regulatory agencies, and the results are broadly positive, though the strength of evidence varies between agents.

Semaglutide demonstrated a significant 26% reduction in MACE in the SUSTAIN-6 trial. Liraglutide showed a 13% reduction in MACE in the LEADER trial. Dulaglutide showed cardiovascular benefits extending to patients at lower cardiovascular risk in the REWIND trial. Tirzepatide's large-scale cardiovascular outcomes trial, SURPASS-CVOT, showed non-inferiority to dulaglutide for MACE, with emerging signals of benefit that are expected to be confirmed in further studies. Exenatide showed cardiovascular neutrality in the EXSCEL trial — it did not increase events but did not produce a statistically significant reduction either.

In terms of renal protection, semaglutide has strong emerging data, and newer agents in development suggest the class may have growing kidney-protective properties. For patients already diagnosed with chronic kidney disease or heart failure, your prescriber will weigh these outcome trial results carefully when choosing between agents.

• Semaglutide has the strongest published MACE reduction data in the GLP-1 class
• Liraglutide is well evidenced for high-risk cardiovascular patients
• Dulaglutide showed broader cardiovascular benefit extending to lower-risk patients
• Tirzepatide cardiovascular outcomes data is maturing but shows promising signals
• All approved GLP-1 agonists are at minimum cardiovascular neutral

Side Effects and Tolerability Across GLP-1 Treatments

One of the most common questions people ask before starting a GLP-1 agonist is what the side effects are like. The good news is that all agents in this class share a broadly similar side effect profile, since they all work through the same fundamental mechanism. The most frequently reported side effects are gastrointestinal — nausea, vomiting, diarrhoea, constipation, and bloating. These tend to be most pronounced when starting treatment or increasing the dose, and they typically settle within a few weeks for most people.

Tirzepatide tends to produce slightly more gastrointestinal side effects than semaglutide at equivalent dose stages, particularly at the higher doses, though individual experience varies considerably. Liraglutide, as a once-daily injection, may produce more consistent gastrointestinal exposure than once-weekly formulations, which some patients find more difficult to tolerate. Exenatide, particularly in the twice-daily formulation, has one of the higher rates of nausea in the class. For more detailed information on how these medications can affect your body day to day, the guide on understanding side effects when starting GLP-1 treatment is an excellent resource.

Other considerations include injection site reactions, rare reports of pancreatitis, and the theoretical concern about thyroid C-cell tumours seen in rodent studies — though this has not been confirmed in human populations. Importantly, none of the approved GLP-1 agonists carry a meaningful hypoglycaemia risk when used without sulphonylureas or insulin. This makes them significantly safer in terms of acute glucose emergencies than older drug classes.

• Nausea and vomiting are the most common side effects and usually resolve with time
• Once-weekly formulations generally have better tolerability than daily or twice-daily options
• GLP-1 agonists do not cause hypoglycaemia when used as monotherapy
• Pancreatitis is a rare but serious adverse event to be aware of
• Gradual dose escalation substantially reduces gastrointestinal side effect burden

GLP-1 Treatment Comparison Table

Medication	Brand Name	Dosing Frequency	HbA1c Reduction	Average Weight Loss	MACE Evidence	NHS Availability
Tirzepatide	Mounjaro	Once weekly	Up to 2.46%	Up to 13.1kg	Non-inferior; favourable signals	Limited (private/some NHS)
Semaglutide (injectable)	Ozempic	Once weekly	1.2% – 1.86%	4 – 6.7kg	Significant MACE reduction (SUSTAIN-6)	Yes (NICE approved)
Semaglutide (oral)	Rybelsus	Once daily	1.0% – 1.4%	2 – 4kg	Emerging data	Yes (NICE approved)
Dulaglutide	Trulicity	Once weekly	1.0% – 1.6%	1 – 3kg	Significant reduction (REWIND)	Yes (NICE approved)
Liraglutide	Victoza	Once daily	1.0% – 1.5%	2 – 4kg	Significant reduction (LEADER)	Yes (NICE approved)
Exenatide	Byetta / Bydureon	Twice daily / Once weekly	0.8% – 1.5%	2 – 3kg	Neutral (EXSCEL)	Yes (NICE approved)

Key Takeaways

• Tirzepatide (Mounjaro) currently leads the GLP-1 class in terms of both HbA1c reduction and weight loss, making it an outstanding option for people with type 2 diabetes who also need to manage their weight
• Semaglutide (Ozempic) is a highly effective and well-evidenced option with robust cardiovascular outcomes data, particularly suited to patients with existing heart disease
• Older agents such as liraglutide, dulaglutide, and exenatide remain effective and have established safety profiles, but are generally less potent than the newer options
• The best GLP-1 agonist for any individual depends on their HbA1c target, weight goals, cardiovascular risk, injection frequency preference, and tolerability profile
• GLP-1 agonists as a class outperform most other non-insulin diabetes medications in terms of glucose lowering, weight reduction, and cardiovascular benefit when used appropriately

When to Seek Professional Advice

Choosing between different GLP-1 agonists — or between a GLP-1 agonist and another class of diabetes medication — is a decision that should always be made in collaboration with a qualified healthcare professional. Your GP, diabetes specialist nurse, or diabetologist will review your full medical history, current HbA1c, kidney function, cardiovascular risk factors, and any other medications you take before making a recommendation.

You should seek professional advice promptly if:

• Your HbA1c has not improved meaningfully after three to six months on your current treatment
• You experience persistent or severe gastrointestinal side effects that are affecting your quality of life
• You develop signs of hypoglycaemia, particularly if you are also taking a sulphonylurea or insulin
• You experience severe abdominal pain that could suggest pancreatitis
• You are pregnant, planning a pregnancy, or breastfeeding, as GLP-1 agonists are generally contraindicated in these situations
• You are considering switching from one GLP-1 agonist to another and want guidance on how to do so safely

It is also worth asking your prescriber about the role of lifestyle modification alongside medication. Diet, physical activity, and sleep quality all continue to matter even when you are on a GLP-1 agonist. For those curious about how GLP-1 treatment interacts with wider health goals, the guide on how hot weather affects type 2 diabetes provides useful seasonal management advice.

Scientific References

1. NICE Guideline NG28 – Type 2 Diabetes in Adults: Management. National Institute for Health and Care Excellence, UK.
2. Diabetes UK – Type 2 Diabetes Clinical Care Recommendations. Diabetes UK Professional Resources.
3. Frías JP et al. – Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. British Medical Journal / NEJM-referenced analysis, 2022.

Frequently Asked Questions

Which GLP-1 agonist is most effective for lowering HbA1c in type 2 diabetes?

Tirzepatide (Mounjaro) currently shows the greatest HbA1c reductions in clinical trials, often achieving reductions of over 2% from baseline, making it one of the most potent options available.

Can GLP-1 agonists replace metformin for type 2 diabetes?

GLP-1 agonists are usually added to existing therapy rather than replacing metformin outright, though your prescriber may adjust your regimen based on individual response and tolerability.

Are GLP-1 agonists available on the NHS for type 2 diabetes?

Yes, several GLP-1 agonists including semaglutide and dulaglutide are available on the NHS for type 2 diabetes, subject to NICE eligibility criteria and prescriber assessment.

How long does it take to see results with a GLP-1 agonist for type 2 diabetes?

Most people begin to notice improvements in blood glucose levels within four to eight weeks, with maximum benefits typically seen after three to six months of consistent use.